Theradiag Reports Revenue of €6.3 Million for the First Half of 2022, Up 14.3%
July 18 2022 - 1:30AM
Business Wire
- Solid growth of 9.3% for Theranostics
- Strong growth of 19.3% in IVD (In Vitro Diagnostics)
activity
- Cash position of €6.0 million on June 30, 2022, in line with
the budget
Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company
specializing in in vitro diagnostics and Theranostics, today
announced its half-year revenue and cash position on June 30, 2022,
data that is currently being audited.
H1 2022 revenue of €6.3 million
In thousands of euros
June 30, 2022
June 30, 2021
Change
Revenue*
6,264
5,482
+14.3%
of which Theranostics revenue
3,024
2,766
+9.3%
of which IVD revenue
3,240
2,716
+19.3%
*Data currently being audited
Over the six months to June 30, 2022, Theradiag generated
revenue of €6.3 million, compared with €5.5 million in the first
half of 2021, giving growth of 14.3%.
Theranostics activity recorded another semester of solid
growth, with revenue increasing by 9.3% to more than €3.0 million
on June 30, 2022. This activity keeps on growing thanks to dynamic
sales of the automated i-Track10 driven by an expanding range of
i-Tracker® tests adapted to this analyzer that thus allows the
development of individualized therapeutic monitoring of even more
biotherapies.
In France, Theranostics saw a solid level of activity with sales
increasing by 10.5% to over €1 million. Abroad, Theranostics
activity also generated satisfactory sales of approximately €2.0
million, up 8.7% compared with the first half of 2021. Moreover,
the Company is in a period of reflection in order to optimize its
commercial activities on the North American market.
IVD (In Vitro Diagnostics) activity recorded strong sales
growth of 19.3% to over €3.2 million on June 30, 2022. This
activity achieved a particularly noteworthy performance in France,
where sales jumped by 29.3% to €2.1 million. These exceptional
performances are the result of non-recurrent commercial
opportunities. Indeed, during the first half of this year,
Theradiag recorded some opportunistic sales of diagnostic
instruments, notably to the veterinary sector, and logged sales of
genetic tests that were temporarily increased before the closure
and resumption of this distribution line.
Cash position
Theradiag had a net cash position of €6.0 million on June 30,
2022, versus €7.1 million on December 31, 2021. This level is in
line with the Company’s roadmap outlined at the time of the rights
issue carried out in October 2021.
Bertrand de Castelnau, Theradiag’s CEO, commented:
“Theradiag is continuing to record solid commercial performances in
the first half of 2022. We were able to maintain our customary
growth in Theranostics and make the most of market opportunities in
in vitro diagnostics. Along with this good sales dynamic, strategic
and structural milestones were achieved by the Company in terms of
R&D, such as the launch of ez-Track1 that is accelerating our
differentiation in biotherapy monitoring and strengthening our
leadership position on this market. Moreover, Theradiag has taken
the implementation of IVDR* onboard and is focusing its attention
on the next measures imposed by this new regulation. In the second
half of 2022, we will strive to continue implementing our strategic
plan that will allow us to improve all our financial
indicators.”
Pierre Morgon, Chairman of Theradiag’s Board of
Directors, added: “Theradiag keeps on developing its
Theranostics activity, which is the cornerstone of its growth
strategy, and will remain agile by seizing any opportunities that
arise on the IVD market. This strategy is enabling Theradiag to
establish its leadership position on its key markets, which have
excellent prospects.”
Reminder of the main H1 2022 highlights
- January 2022: Signing of a distribution agreement with BIOSYNEX
of their AMPLIQUICK SARS-CoV-2 PCR test
- May 2022: Launch of two new i-Tracker® kits: i-Tracker®
Certolizumab and i-Tracker® Anti-Certolizumab
- May 2022: Launch of ez-Track1, a Point-of-Care Testing solution
for therapeutic drug monitoring
- June 2022: Partnership with Quotient Limited to advance
autoimmune disease diagnostics
Next financial press release:
- H1 2022 results, on Monday September 19, 2022, before
market
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2021, the Company posted revenue of €11.1 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan. For more
information about Theradiag, please visit our website:
https://www.theradiag.com/
____________________________ * New EU regulation covering in
vitro medical devices justifying the granting or renewal of CE
Marking since May 26, 2022.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220717005002/en/
Theradiag Bertrand de Castelnau CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent / Quentin Massé Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theradiag (EU:ALTER)
Historical Stock Chart
From Apr 2023 to Apr 2024